UNCY Description — Unicycive Therapeutics Inc
Unicycive Therapeutics is a biotechnology company focused on developing treatments for certain medical conditions. Co.'s existing development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD); and UNI 494, for treatment of acute kidney injury (AKI). CKD is the gradual loss of kidney function that can get worse over time leading to lasting damage. AKI is a sudden episode of kidney failure or kidney damage (within the first 90 days of injury). After 90 days, the patient is considered to have progressed into CKD.